SYRS Insider Trading

Insider Ownership Percentage: 12.26%
Insider Buying (Last 12 Months): $206,490.57
Insider Selling (Last 12 Months): $225,493.85

Syros Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Syros Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Syros Pharmaceuticals Share Price & Price History

Current Price: $0.03
Price Change: Price Decrease of -0.0033 (-10.86%)
As of 03/28/2025 04:59 PM ET

This chart shows the closing price history over time for SYRS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.03Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Syros Pharmaceuticals (NASDAQ:SYRS)

91.47% of Syros Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SYRS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$11kbought$1ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal InflowsTotal Outflows
Syros Pharmaceuticals logo
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Read More on Syros Pharmaceuticals

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.14
Low: $0.03
High: $0.22

52 Week Range

Now: $0.03
Low: $0.02
High: $6.93

Volume

640,593 shs

Average Volume

8,051,844 shs

Market Capitalization

$727,147.20

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of Syros Pharmaceuticals?

Syros Pharmaceuticals' top insider shareholders include:
  1. Srinivas Akkaraju (Director)
  2. Jason Haas (CFO)
  3. Conley Chee (CEO)
  4. Nancy A Simonian (Director)
  5. David Roth (Insider)
  6. Richard A Young (Director)
  7. Eric R Olson (Insider)
Learn More about top insider investors at Syros Pharmaceuticals.

Who are the major institutional investors of Syros Pharmaceuticals?

Syros Pharmaceuticals' top institutional shareholders include:
  1. Affinity Asset Advisors LLC — 0.00%
  2. Two Sigma Securities LLC — 0.40%
  3. Torno Capital LLC — 0.00%
  4. FNY Investment Advisers LLC — 0.00%
  5. Citadel Advisors LLC — 0.00%
  6. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Syros Pharmaceuticals stock.

Which major investors are selling Syros Pharmaceuticals stock?

During the previous quarter, SYRS stock was sold by these institutional investors:
  1. Citadel Advisors LLC
  2. FNY Investment Advisers LLC
In the last year, company insiders that have sold Syros Pharmaceuticals company stock include:
  1. Srinivas Akkaraju (Director)
  2. Jason Haas (CFO)
  3. Conley Chee (CEO)
Learn More investors selling Syros Pharmaceuticals stock.

Which major investors are buying Syros Pharmaceuticals stock?

In the previous quarter, SYRS stock was bought by institutional investors including:
  1. Affinity Asset Advisors LLC
  2. Two Sigma Securities LLC
  3. Torno Capital LLC
During the previous year, these company insiders have bought Syros Pharmaceuticals stock:
  1. Srinivas Akkaraju (Director)
  2. Jason Haas (CFO)
  3. Conley Chee (CEO)
Learn More investors buying Syros Pharmaceuticals stock.